<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025295</url>
  </required_header>
  <id_info>
    <org_study_id>XZ2015020</org_study_id>
    <nct_id>NCT03025295</nct_id>
  </id_info>
  <brief_title>The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine</brief_title>
  <official_title>The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to investigate the difference of plasma orexin A levels between&#xD;
      Dexmedetomidine group and controlled group at emergence time from total intravenous&#xD;
      anesthesia who will undergo elective lumbar surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGNING: Fifty-one patients with ASA physical status I or II scheduled for elective surgery&#xD;
      under general anesthesia (lasting for 2h to 4h) were enrolled. Anesthesia was induced with&#xD;
      propofol 1-2mg/kg and sufentanyl 0.2-0.3μg/kg. Following muscle relaxation with iv&#xD;
      cisatracurium besylate 0.2mg/kg endotracheal intubation was performed. Anesthesia was&#xD;
      maintained with target controlled infusion propofol (targeted concentration:2-5ug/ml ) and&#xD;
      remifentanil (targeted concentration: 2-6ng/ml ). Muscle relaxation was maintained with&#xD;
      intermittent, but it do not injected in 1h before surgery completion. Propofol and&#xD;
      remifentanil were titrated to maintain the bispectral index (BIS) between 40 and 60 during&#xD;
      anesthesia. The end-tidal carbon dioxide level was maintained between 30 and 40 mmHg by&#xD;
      controlled mechanical ventilation. When the surgery was completed the investigators adjust&#xD;
      the targeted concentration of propofol 2ug/ml and targeted concentration of remifentanil to&#xD;
      2ng/ml then stop all anesthetics. Dexmedetomidine group target controlled infusion&#xD;
      dexmedetomidine (induction dose 1ug/kg with 10min, maintain dose 0.4ug/kg/h until 30min&#xD;
      before surgery completion). Control group infusion same saline. Record time from stopping&#xD;
      anesthetics to emergence and total doses of anesthetics. Arterial blood (2.5ml) was collected&#xD;
      at the following time, such as before and 1h after induction of anesthesia, at emergence (1&#xD;
      min after tracheal extubation) and half an hour after tracheal extubation. 2.0ml Arterial&#xD;
      blood was centrifuged at 3000 rpm for 15min at -4 ◦C in order to separate plasma then stored&#xD;
      at -80 ◦C until assay for orexin A concentrations. 0.5ml Arterial blood was measured blood&#xD;
      glucose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>orexin A concentrations</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group given equal volume of saline with the dexmedetomidine group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine is common used to improve the prognosis and life quality of patients.</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <other_name>Dexmedetomidine is a highly selective α2-adrenoceptor agonist.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>It is safe Placebo.</description>
    <arm_group_label>Saline group</arm_group_label>
    <other_name>It is safe Placebo.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is Adult (≥18 years old and ≤60 years old)&#xD;
&#xD;
          2. Participants with a Body Mass Index (BMI) 20-25 kg/m2&#xD;
&#xD;
          3. Participants with ASA physical status Ⅰor Ⅱ&#xD;
&#xD;
          4. Participants with Heart function rating Ⅰor Ⅱ&#xD;
&#xD;
          5. Patients will undergo elective surgery and general anesthesia&#xD;
&#xD;
          6. The operation time is 2h to 4h.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is a pregnant woman or a nursing mother.&#xD;
&#xD;
          2. Participants have a history of narcotics allergic reactions.&#xD;
&#xD;
          3. Indices of liver or kidney function is twice higher than normal.&#xD;
&#xD;
          4. Participants have a history or diagnosis of depression.&#xD;
&#xD;
          5. Participants have a history of Brain Trauma.&#xD;
&#xD;
          6. Participants have a history of narcotics addiction or drug addiction.&#xD;
&#xD;
          7. Participants or his family have an International Classification of Sleep&#xD;
&#xD;
          8. Disorders diagnosis of obstructive sleep apnea syndrome.&#xD;
&#xD;
          9. Patients are refuse this trail or are not able to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihua Wang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anesthesiology department of General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

